We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Novel ALS Therapy in Human Clinical Trials

News   Jul 17, 2018 | Original Story by Tamara Bhandari for WUSTL

 
Novel ALS Therapy in Human Clinical Trials

Robert Bucelli, MD, PhD, measures Gregory Easter's neuromuscular function. Easter, who has an inherited form of amytrophic lateral sclerosis, a fatal neuromuscular disease, is taking part in a clinical trial to evaluate an experimental drug. New research at Washington University School of Medicine in St. Louis shows the drug extends survival and reverses some neuromuscular damage in mice and rats and may help people whose disease is caused by mutations in the gene SOD1. Credit: Mike Worful, WUSTL.

 
 
 

RELATED ARTICLES

Common Disease Mechanism for ALS and Frontotemporal Dementia

News

Findings suggest mutations leading to accumulation of RNA-binding proteins to blame for disease, and could offer route for early diagnosis

READ MORE

Microfluidically-linked BBB and Brain-chips Opens Another Dimension for Neurological Research

News

Linked BBB and brain-chips strike the perfect balance of complexity and simplicity for studying the neurovascular unit.

READ MORE

Misery Loves Company -for Teens

News

Study on adolescent friendships offers support for the belief that misery really does love company.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Neuroscience

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE